Becker Muscular Dystrophy Clinical Trial
the Investigator will test the hypothesis that short term PDE5A inhibition (with tadalafil) will reduce post-exercise edema by MRI in males with Becker Muscular Dystrophy.
Becker muscular dystrophy (BMD) is a rare, progressive and fatal muscle disease. Tadalafil is
approved by the FDA for the treatment of erectile dysfunction and pulmonary hypertension.
This class of medication improves muscle blood flow in a mouse model of muscular dystrophy,
prevents post-exercise muscle edema, and alleviates post-exercise muscle fatigue. To begin to
translate this work from the mouse into actual patients with muscular dystrophy, the
Investigator group recently demonstrated that a single dose of tadalafil can improve blood
flow regulation in boys with Duchenne muscular dystrophy and men with BMD. the Investigator
now wish to test the hypothesis that acute treatment with Tadalafil can prevent post-exercise
muscle edema in men with BMD.
the Investigator will recruit men with BMD, and healthy age-matched controls, ages 15-55y who
are ambulatory and without heart failure.
Visit 1: Participants will undergo informed consent, physical exam and medical history
screening, electrocardiogram, blood pressure monitoring, blood chemistry testing,
echocardiogram (ejection fraction measurement), and evaluation of skeletal muscle blood flow.
Patients, but not controls, will also undergo a muscle biopsy.
Visit 2 - 4: Participants will undergo baseline magnetic resonance imaging of the forearm
muscle, followed by rhythmic forearm muscle exercise (handgrip). MRI will then be repeated
2-, 4-, 24-, and 48 hours following the rhythmic handgrip exercise.
Patients with BMD will then be randomized in a 3:1 fashion to tadalafil vs. placebo.
Visit 5-7: Using a standard double-blind cross-over design, patients will be treated with
either tadalafil or placebo. Magnetic resonance imaging of the forearm muscle will be
performed to establish baseline measurements. Patients will then repeat the rhythmic handgrip
exercise protocol performed on Visit 2, followed by MRI 2-, 4-, 24-, and 48 hours following
exercise.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT02847975 -
Sodium Nitrate to Improve Blood Flow
|
Phase 1 | |
Completed |
NCT02147639 -
Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy
|
Phase 2/Phase 3 | |
Recruiting |
NCT02069756 -
The Duchenne Registry
|
||
Completed |
NCT04585464 -
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
|
Phase 1 | |
Recruiting |
NCT04668716 -
Brain Involvement in Dystrophinopathies Part 2
|
||
Completed |
NCT03236662 -
(-)- Epicatechin Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT01350154 -
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients
|
Phase 2 | |
Enrolling by invitation |
NCT06066580 -
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
|
Phase 2 | |
Not yet recruiting |
NCT06363526 -
Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
|
N/A | |
Recruiting |
NCT05409079 -
Schulze Muscular Dystrophy Ability Clinical Study
|
N/A | |
Completed |
NCT01856868 -
Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)
|
Phase 1/Phase 2 | |
Completed |
NCT01557400 -
Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
|
Phase 3 | |
Recruiting |
NCT02109692 -
Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies
|
N/A | |
Recruiting |
NCT03057002 -
UTSW HP [13-C] Pyruvate Injection in HCM
|
||
Recruiting |
NCT04583917 -
Brain Involvement in Dystrophinopathies Part 1
|
||
Completed |
NCT02207283 -
PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy
|
Phase 4 | |
Completed |
NCT00873782 -
Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
|
Phase 1 | |
Not yet recruiting |
NCT05715957 -
Follow-up Study on Female Carriers With DMD Gene Variants
|